NCT00003789View on ClinicalTrials.gov

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

PHASE3CompletedINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

January 31, 2004

Conditions

Recurrent MelanomaStage III Melanoma

Interventions

DRUG

isolated limb perfusion

Undergo isolated limb perfusion

DRUG

melphalan

Given via limb perfusion

BIOLOGICAL

recombinant tumor necrosis factor family protein

Given via slow injection into the arterial line

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27705

American College of Surgeons Oncology Group, Durham

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00003789 - Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg | Biotech Hunter | Biotech Hunter